TY - JOUR
T1 - Non-intensive acute myeloid leukemia therapies for older patients
AU - Babakhanlou, Rodrick
AU - Ravandi-Kashani, Farhad
N1 - Funding Information:
This paper was not funded.
Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Introduction: Acute myeloid leukemia (AML) is an aggressive disease predominantly affecting the elderly population. The elderly population represents a challenging group to treat and the prognosis is generally poor with significantly worse treatment outcomes compared to the younger population. While the goal of treatment for younger fit patients is cure and includes intensive chemotherapy and stem cell transplantation, these strategies are not always feasible for elderly unfit patients due to increased frailty, co-morbidities, and, subsequently, an increased risk of treatment-related toxicity and mortality. Areas covered: This review will discuss both patient- and disease-related factors, outline prognostication models and summarize current treatment options, including intensive and less intensive treatment strategies and novel agents. Expert opinion: Although recent years have seen major advances in the development of low-intensity therapies, there is still a lack of consensus on the optimal treatment for this patient group. Because of the heterogeneity of the disease, personalizing the treatment strategy is important and curative-oriented approaches should be selected wisely, rather than following a rigid hierarchical algorithm.
AB - Introduction: Acute myeloid leukemia (AML) is an aggressive disease predominantly affecting the elderly population. The elderly population represents a challenging group to treat and the prognosis is generally poor with significantly worse treatment outcomes compared to the younger population. While the goal of treatment for younger fit patients is cure and includes intensive chemotherapy and stem cell transplantation, these strategies are not always feasible for elderly unfit patients due to increased frailty, co-morbidities, and, subsequently, an increased risk of treatment-related toxicity and mortality. Areas covered: This review will discuss both patient- and disease-related factors, outline prognostication models and summarize current treatment options, including intensive and less intensive treatment strategies and novel agents. Expert opinion: Although recent years have seen major advances in the development of low-intensity therapies, there is still a lack of consensus on the optimal treatment for this patient group. Because of the heterogeneity of the disease, personalizing the treatment strategy is important and curative-oriented approaches should be selected wisely, rather than following a rigid hierarchical algorithm.
KW - Acute myeloid leukemia
KW - elderly population
KW - hypomethylating agents
KW - low-intensity therapy
KW - targeted therapy
KW - treatment options
UR - http://www.scopus.com/inward/record.url?scp=85149544534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149544534&partnerID=8YFLogxK
U2 - 10.1080/17474086.2023.2184342
DO - 10.1080/17474086.2023.2184342
M3 - Review article
C2 - 36864772
AN - SCOPUS:85149544534
SN - 1747-4086
VL - 16
SP - 171
EP - 180
JO - Expert review of hematology
JF - Expert review of hematology
IS - 3
ER -